Clinical trials: Type 2 Diabetic
- Condition Type 2 Diabetic
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Diabetes Mellitus, Type 2
Renal Impairment in Type 2 Diabetic Subjects
The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with…
- Trial name
- NCT00554450
- Testing
- Dapagliflozin
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics
The main objective of the study is to demonstrate the safety and efficacy of the EndoBarrier Flow Restrictor in the glycemic control of diabetes in subjects with Type 2 diabetes.
- Trial name
- NCT00973960
- Where
- Chile
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01900834
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Type 2 Diabetes
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes.
- Trial name
- NCT02443753
- Testing
- EndoBarrier SANS
- Where
- Malaysia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2, Diabetic Complication
mHealth Titration and Management
The principal objective of this application is to improve glycemic control of diabetic patients treated with basal insulin through use of an innovative, FDA-cleared smartphone-based insulin titration application connected to…
- Trial name
- NCT03908762
- Testing
- iSage App with connected glucometer, Magnet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amalgam Rx, Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
A Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product (FCDP) of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin /10 mg Dapagliflozin /1000 mg Metformin XR…
- Trial name
- NCT03169959
- Testing
- 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
FTIH of ECC5004 in Healthy and Diabetic Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT05654831
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eccogene
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics) of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to evaluate the effect of food on the PK of JTT-251…
- Trial name
- NCT02106585
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Shionogi Inc.
Diabetes Mellitus, Type 2
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
- Trial name
- NCT01396161
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects
The purpose of this study is to investigate microvascular endothelial function in the retina of lean, obese, and type 2 diabetic subjects and to compare microvascular endothelial function in the retina with several other…
- Trial name
- NCT01241370
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ELAB-Logistics
Normal Eyes of Subjects Without Diabetes Mellitus, Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN
Repeatability of Static & Dynamic Composite Confocal Microscopy for Assessment of the Corneal Nerve Fiber Plexus in Early Diabetic Polyneuropathy
This prospective study was was divided into 2 parts and carried out at 2 sites in Germany. Part 1 assessed Repeatability in healthy, non-diabetic population (Group "control").
- Conditions
- Normal Eyes of Subjects Without Diabetes Mellitus, Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN, Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
- Trial name
- NCT05326958
- Testing
- HRT RCM, HRT RCM-E
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Diabetes Type 2, Periodontitis
Exploratory Study of Iocide Oral Rinse in a Diabetic Population
The goals of this exploratory study are to 1)examine an investigational oral rinse as an adjunctive agent to scaling and root planing in treating chronic periodontitis in a periodontitis-susceptible diabetes population, and 2)…
- Trial name
- Diabetes (NCT00801164)
- Testing
- Frio Mouth Rinse
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biomedical Development Corporation
Diabetes Mellitus
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of…
- Trial name
- NCT02120976
- Testing
- JTT-252
- Where
- 2 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shionogi Inc.
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice
Improving Diabetic Patient Health Through Assistive-Reading Technology
Type 2 Diabetes Mellitus (T2DM) affects over 30 million Americans and requires patients to competently manage their conditions at home.
- Conditions
- Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
- Trial name
- NCT05337306
- Testing
- GogyUp Reader
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- GogyUp Inc
Diabetes Mellitus, Type 2
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after…
- Trial name
- NCT01372163
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Diabetes, Diabetes Mellitus, Type 2
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers
This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart 70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30 (NN-X14Mix30) in healthy volunteers.
- Trial name
- NCT01538511
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 30
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
20 eligible subjects will be enrolled into the treatment phase of the trial.
- Trial name
- NCT00642538
- Testing
- MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation